

Alvin H Schmaier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4255710/publications.pdf>

Version: 2024-02-01

215
papers

9,627
citations

31976
53
h-index

40979
93
g-index

246
all docs

246
docs citations

246
times ranked

8913
citing authors

#	ARTICLE	IF	CITATIONS
1	Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes. <i>Blood</i> , 1997, 90, 3819-3843.	1.4	538
2	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1183-1189.	3.8	398
3	Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*. <i>Journal of Biological Chemistry</i> , 2007, 282, 22254-22266.	3.4	341
4	The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 28-39.	3.8	298
5	In vivo roles of factor XII. <i>Blood</i> , 2012, 120, 4296-4303.	1.4	285
6	Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator. <i>Journal of Biological Chemistry</i> , 2002, 277, 17962-17969.	3.4	237
7	Use of Factor IX Complex in Warfarin-related Intracranial Hemorrhage. <i>Neurosurgery</i> , 1999, 45, 1113-1119.	1.1	220
8	Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary Angioedema. <i>New England Journal of Medicine</i> , 1983, 308, 1050-1053.	27.0	196
9	Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 4727-4731.	8.2	180
10	Platelet Aggregation Testing in Platelet-Rich Plasma. <i>American Journal of Clinical Pathology</i> , 2005, 123, 172-183.	0.7	172
11	High Molecular Weight Kininogen Regulates Prekallikrein Assembly and Activation on Endothelial Cells: A Novel Mechanism for Contact Activation. <i>Blood</i> , 1998, 91, 516-528.	1.4	156
12	Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. <i>Blood</i> , 2002, 99, 3585-3596.	1.4	155
13	The plasma kallikrein-kinin system: its evolution from contact activation. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2323-2329.	3.8	153
14	Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis. <i>American Journal of Pathology</i> , 2002, 160, 1867-1875.	3.8	152
15	Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. <i>Thrombosis Research</i> , 2010, 125, 210-215.	1.7	146
16	Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases. <i>Arthritis and Rheumatism</i> , 2000, 43, 1891-1896.	6.7	142
17	Detection of Amide I Signals of Interfacial Proteins in Situ Using SFG. <i>Journal of the American Chemical Society</i> , 2003, 125, 9914-9915.	13.7	140
18	The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R1-R13.	1.8	138

#	ARTICLE	IF	CITATIONS
19	D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1312-1317.	3.4	136
20	Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. <i>Blood</i> , 2008, 111, 1274-1281.	1.4	136
21	The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. <i>Thrombosis Research</i> , 1984, 33, 51-67.	1.7	134
22	Increased Platelet and Microparticle Activation in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 340-346.	2.1	131
23	Prolylcarboxypeptidase regulates food intake by inactivating $\hat{I}\pm$ -MSH in rodents. <i>Journal of Clinical Investigation</i> , 2009, 119, 2291-303.	8.2	122
24	Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5. <i>Journal of Biological Chemistry</i> , 1995, 270, 19256-19261.	3.4	118
25	Recombinant prolylcarboxypeptidase activates plasma prekallikrein. <i>Blood</i> , 2004, 103, 4554-4561.	1.4	114
26	Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. <i>Blood</i> , 2001, 97, 2342-2350.	1.4	112
27	Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2160-2171.	8.2	112
28	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020, 58, 102907.	6.1	110
29	Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. <i>Translational Research</i> , 1996, 127, 612-620.	2.3	107
30	Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. <i>Blood</i> , 2010, 115, 5111-5120.	1.4	103
31	Factor XII and uPAR upregulate neutrophil functions to influence wound healing. <i>Journal of Clinical Investigation</i> , 2018, 128, 944-959.	8.2	103
32	The elusive physiologic role of Factor XII. <i>Journal of Clinical Investigation</i> , 2008, 118, 3006-9.	8.2	101
33	Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. <i>Blood</i> , 2011, 117, 3929-3937.	1.4	95
34	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. <i>Urology</i> , 2002, 60, 760-765.	1.0	90
35	The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. <i>Journal of Clinical Investigation</i> , 2002, 109, 1007-1009.	8.2	90
36	Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1998, 80, 74-81.	3.4	89

#	ARTICLE	IF	CITATIONS
37	Thrombotic Microangiopathy in Haematopoietic Stem Cell Transplantation. <i>Drugs</i> , 2009, 69, 183-198.	10.9	89
38	Bradykinin and Its Metabolite, Arg-Pro-Pro-Gly-Phe, Are Selective Inhibitors of tPA -Thrombin-Induced Platelet Activation. <i>Circulation</i> , 1996, 94, 517-528.	1.6	87
39	Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H1821-H1829.	3.2	86
40	Heparan Sulfate Modulates Kinin Release by <i>Trypanosoma cruzi</i> through the Activity of Cruzipain. <i>Journal of Biological Chemistry</i> , 2002, 277, 5875-5881.	3.4	86
41	Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. <i>Blood</i> , 2006, 108, 192-199.	1.4	82
42	Angiotensin 1-7 and Mas decrease thrombosis in <i>Bdkrb2</i> ^{-/-} mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. <i>Blood</i> , 2013, 121, 3023-3032.	1.4	80
43	Contact Activation: A Revision. <i>Thrombosis and Haemostasis</i> , 1997, 78, 101-107.	3.4	79
44	Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. <i>International Immunopharmacology</i> , 2008, 8, 161-165.	3.8	78
45	Reduced thrombosis in <i>Klkb1</i> ^{-/-} mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. <i>Blood</i> , 2015, 125, 710-719.	1.4	76
46	Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. <i>Diabetes</i> , 2003, 52, 1215-1221.	0.6	68
47	Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 65-72.	3.7	68
48	A Prospective Study of Platelets and Plasma Proteolytic Systems during the Early Stages of Rocky Mountain Spotted Fever. <i>New England Journal of Medicine</i> , 1988, 318, 1021-1028.	27.0	67
49	Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field. <i>American Journal of Clinical Pathology</i> , 2005, 123, 172-183.	0.7	66
50	Initiation of Blood Coagulation at Artificial Surfaces. <i>Annals of the New York Academy of Sciences</i> , 1987, 516, 253-267.	3.8	61
51	Protease nexin-2/amyloid β -protein precursor in blood is a platelet-specific protein. <i>Biochemical and Biophysical Research Communications</i> , 1991, 175, 15-21.	2.1	61
52	Interaction of Thrombin with PAR1 and PAR4 at the Thrombin Cleavage Site. <i>Biochemistry</i> , 2007, 46, 8603-8610.	2.5	58
53	Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. <i>FEBS Letters</i> , 2002, 523, 167-170.	2.8	57
54	Prolylcarboxypeptidase promotes angiogenesis and vascular repair. <i>Blood</i> , 2013, 122, 1522-1531.	1.4	56

#	ARTICLE	IF	CITATIONS
55	Neonatal purpura fulminans in association with factor V R506Q mutation. Journal of Pediatrics, 1996, 128, 706-709.	1.8	55
56	Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. International Immunopharmacology, 2002, 2, 1841-1849.	3.8	55
57	The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. Journal of Clinical Investigation, 2002, 109, 1007-1009.	8.2	55
58	Genetic polymorphism of the β_2 -adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. American Journal of Hypertension, 1995, 8, 863-869.	2.0	53
59	Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Current Opinion in Hematology, 2000, 7, 261-265.	2.5	53
60	Effect of negatively charged activating compounds on inactivation of factor XIIa by C1 ₁ , inhibitor. Archives of Biochemistry and Biophysics, 1987, 256, 490-498.	3.0	51
61	Mechanism of Epinephrine-Induced Platelet Aggregation. Hypertension, 1998, 31, 603-607.	2.7	50
62	Myeloperoxidase Interacts with Endothelial Cell-Surface Cytokeratin 1 and Modulates Bradykinin Production by the Plasma Kallikrein-Kinin System. American Journal of Pathology, 2007, 171, 349-360.	3.8	50
63	Physiologic activities of the Contact Activation System. Thrombosis Research, 2014, 133, S41-S44.	1.7	49
64	The contact activation system: Biochemistry and interactions of these surface-mediated defense reactions. Critical Reviews in Oncology/Hematology, 1986, 5, 57-85.	4.4	48
65	Protease Nexin-2/Amyloid β -Protein Precursor Inhibits Factor Xa in the Prothrombinase Complex. Journal of Biological Chemistry, 1995, 270, 23468-23474.	3.4	46
66	Mapping Binding Domains of Kininogens on Endothelial Cell Cytokeratin 1. Journal of Biological Chemistry, 1999, 274, 7137-7145.	3.4	46
67	Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. American Journal of Physiology - Cell Physiology, 2013, 304, C945-C953.	4.6	44
68	Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 2017, 95, 473-486.	3.9	40
69	High Molecular Weight Kininogen Regulates Prekallikrein Assembly and Activation on Endothelial Cells: A Novel Mechanism for Contact Activation. Blood, 1998, 91, 516-528.	1.4	40
70	Activation of the Plasma Kallikrein/Kinin System on Cells: A Revised Hypothesis. Thrombosis and Haemostasis, 1999, 82, 226-233.	3.4	39
71	Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid β -protein precursor-like protein-2. BBA - Proteins and Proteomics, 1994, 1209, 165-170.	2.1	37
72	Factor IXa Inhibition by Protease Nexin-2/Amyloid β -Protein Precursor on Phospholipid Vesicles and Cell membranes. Biochemistry, 1995, 34, 1171-1178.	2.5	37

#	ARTICLE	IF	CITATIONS
73	A ² PP/APLP2 Family of Kunitz Serine Proteinase Inhibitors Regulate Cerebral Thrombosis. Journal of Neuroscience, 2009, 29, 5666-5670.	3.6	37
74	Mapping the Interaction between High Molecular Mass Kininogen and the Urokinase Plasminogen Activator Receptor. Journal of Biological Chemistry, 2004, 279, 16621-16628.	3.4	34
75	Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H183-H193.	3.2	33
76	Factor V Leiden Inhibits Fibrinolysis In Vivo. Circulation, 2004, 110, 3594-3598.	1.6	32
77	The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2). Blood, 2014, 123, 3828-3831.	1.4	32
78	Plasma kallikrein activates the epithelial sodium channel in vitro but is not essential for volume retention in nephrotic mice. Acta Physiologica, 2018, 224, e13060.	3.8	32
79	Alpha thalassemia screenign in neonates by mean corpuscular volume and mean corpuscular hemoglobin determination. Journal of Pediatrics, 1973, 83, 794-797.	1.8	30
80	The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 492-501.	2.5	30
81	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1748-1760.	2.4	30
82	Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. Journal of Vascular Surgery, 1998, 27, 568-575.	1.1	29
83	Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Current Opinion in Hematology, 2007, 14, 468-480.	2.5	29
84	The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. Journal of Endotoxin Research, 2004, 10, 3-13.	2.5	28
85	Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP. Biochimie, 2017, 135, 72-81.	2.6	28
86	Factor XII – What's important but not commonly thought about. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 599-606.	2.3	28
87	Activation of the Plasma Kallikrein–Kinin System on Endothelial Cells. Proceedings of the Association of American Physicians, 1999, 111, 220-227.	2.0	28
88	Activation of the plasma kallikrein/kinin system on endothelial cell membranes. Immunopharmacology, 1999, 43, 109-114.	2.0	27
89	Factor XI Assembly and Activation on Human Umbilical Vein Endothelial Cells in Culture. Thrombosis and Haemostasis, 2001, 85, 544-551.	3.4	26
90	The Relative Priority of Prekallikrein and Factors XI/XIa Assembly on Cultured Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 43983-43990.	3.4	25

#	ARTICLE	IF	CITATIONS
91	Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. Blood, 2003, 101, 4430-4436.	1.4	24
92	Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair. Journal of Vascular Surgery, 2020, 72, 129-137.	1.1	24
93	Enhanced Plasmin Inhibition by a Reactive Center Lysine Mutant of the Kunitz-type Protease Inhibitor Domain of the Amyloid β -Protein Precursor. Journal of Biological Chemistry, 1995, 270, 22827-22830.	3.4	22
94	The physiologic basis of assembly and activation of the plasma kallikrein/kinin system. Thrombosis and Haemostasis, 2004, 91, 1-3.	3.4	22
95	Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β 1-integrin and VEGFR2. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H305-H320.	3.2	21
96	Alzheimer disease is in part a thrombohemorrhagic disorder. Journal of Thrombosis and Haemostasis, 2016, 14, 991-994.	3.8	21
97	Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis. International Journal of Molecular Sciences, 2020, 21, 6556.	4.1	21
98	Myeloid-related protein-14 regulates deep vein thrombosis. JCI Insight, 2017, 2, .	5.0	21
99	Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems. Pharmacological Research, 2020, 160, 105096.	7.1	20
100	Thrombostatin Inhibits Induced Canine Coronary Thrombosis. Thrombosis and Haemostasis, 1999, 82, 1182-1187.	3.4	19
101	Antithrombotic potential of the contact activation pathway. Current Opinion in Hematology, 2016, 23, 445-452.	2.5	19
102	Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease. Frontiers in Medicine, 2018, 5, 3.	2.6	19
103	Oral thrombostatin FM19 inhibits prostate cancer. Thrombosis and Haemostasis, 2010, 104, 1044-1048.	3.4	18
104	The Williams-Beuren Syndrome—A Window into Genetic Variants Leading to the Development of Cardiovascular Disease. PLoS Genetics, 2012, 8, e1002479.	3.5	18
105	Assessment of whole blood coagulation with a microfluidic dielectric sensor. Journal of Thrombosis and Haemostasis, 2018, 16, 2050-2056.	3.8	18
106	Protease Nexin-2/Amyloid β -Protein Precursor Regulates Factor VIIa and the Factor VIIa—Tissue Factor Complex. Thrombosis Research, 2000, 99, 267-276.	1.7	17
107	Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor). Current Molecular Medicine, 2014, 14, 1173-1185.	1.3	17
108	A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin—Angiotensin Systems. Frontiers in Medicine, 2016, 3, 61.	2.6	16

#	ARTICLE	IF	CITATIONS
109	Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. Blood Advances, 2019, 3, 2312-2316.	5.2	16
110	Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. Blood Advances, 2021, 5, 4741-4751.	5.2	16
111	Kininogen-Cytokeratin 1 Interactions in Endothelial Cell Biology. Trends in Cardiovascular Medicine, 1999, 9, 238-244.	4.9	15
112	Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovascular Research, 2002, 53, 984-992.	3.8	15
113	Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Letters, 2005, 579, 25-29.	2.8	15
114	Factor XII: New life for an old protein. Thrombosis and Haemostasis, 2010, 104, 915-918.	3.4	15
115	A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease. Frontiers in Medicine, 2016, 3, 17.	2.6	15
116	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. British Journal of Haematology, 1991, 79, 296-301.	2.5	14
117	Thrombostatin Inhibits Cyclic Flow Variations in Stenosed Canine Coronary Arteries. Thrombosis and Haemostasis, 2001, 86, 1296-1304.	3.4	14
118	Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology (United Kingdom), 2010, 156, 3660-3668.	1.8	14
119	Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. Clinical Lung Cancer, 2019, 20, e560-e563.	2.6	14
120	Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L596-L602.	2.9	14
121	The hereditary angioedema syndromes. Journal of Clinical Investigation, 2018, 129, 66-68.	8.2	14
122	Left Ventricular Thrombus with Normal Left Ventricular Function and Hyperaggregable Platelets in a Patient with Polycystic Disease of Multiple Organs. American Journal of the Medical Sciences, 1984, 288, 223-227.	1.1	13
123	The Pharmacokinetics of the Kininogens. Thrombosis Research, 1998, 92, 293-297.	1.7	13
124	Transferrin: a blood coagulation modifier. Cell Research, 2020, 30, 101-102.	12.0	13
125	[24] Platelet high-molecular-weight kininogen. Methods in Enzymology, 1989, 169, 276-296.	1.0	12
126	Association of the Prothrombin G20210A Mutation With Factor V Leiden in a Midwestern American Population. American Journal of Clinical Pathology, 2000, 114, 272-275.	0.7	12

#	ARTICLE	IF	CITATIONS
127	Extracorporeal Circulation Without Bleeding. Science Translational Medicine, 2014, 6, 222fs7.	12.4	12
128	Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes, 2016, 65, 498-502.	0.6	12
129	Conformational Changes in Low Molecular Weight Kininogen Alters Its Ability to Bind to Endothelial Cells. Thrombosis and Haemostasis, 1995, 74, 1088-1095.	3.4	12
130	Nomenclature of factor XI and the contact system. Journal of Thrombosis and Haemostasis, 2019, 17, 2216-2219.	3.8	11
131	Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β -Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits. Thrombosis and Haemostasis, 1999, 82, 1474-1481.	3.4	11
132	Factor XII Promotes Leukocyte Inflammation and Its Deficiency Results in Faster Wound Healing. Blood, 2011, 118, 368-368.	1.4	11
133	Von Willebrand factor promoter targets the expression of amyloid β protein precursor to brain vascular endothelial cells of transgenic mice. Journal of Alzheimer's Disease, 2003, 5, 149-158.	2.6	9
134	Synthesis of Novel Peptide Inhibitors of Thrombin-induced Platelet Activation. Chemical Biology and Drug Design, 2006, 68, 235-238.	3.2	8
135	Sweet and Sticky. Journal of the American College of Cardiology, 2007, 50, 1548-1550.	2.8	8
136	Quantitation and characterization of human platelet glycoprotein IIIa by radioimmunoassay. Biochimica Et Biophysica Acta - General Subjects, 1987, 924, 216-224.	2.4	7
137	Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study. Journal of Allergy and Clinical Immunology, 2019, 143, AB41.	2.9	7
138	Modulation of the cell membrane expression of the kininogens regulates the rate of bradykinin delivery to cells. Trends in Cardiovascular Medicine, 1992, 2, 108-114.	4.9	6
139	Gamma Interferon Administration to Patients with Atopic Dermatitis Inhibits Fibrinolysis and Elevates C1 Inhibitor. Thrombosis Research, 1998, 89, 253-261.	1.7	6
140	Laser-light scattering, a new method for continuous monitoring of platelet activation in circulating fluid. Translational Research, 2003, 141, 50-57.	2.3	6
141	Homonymous Hemianopia Caused by Occipital Lobe Infarction in Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. Journal of Neuro-Ophthalmology, 2005, 25, 193-197.	0.8	6
142	Venous and Arterial Thrombosis. , 2014, , 277-296.		6
143	Venous Thromboembolism Chemoprophylaxis in Total Hip and Knee Arthroplasty. JBJS Reviews, 2019, 7, e2-e2.	2.0	6
144	Elevated Neutrophil to Lymphocyte Ratio is Associated with Worse Outcomes after Carotid Endarterectomy in Asymptomatic Patients. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106120.	1.6	6

#	ARTICLE	IF	CITATIONS
145	Aprotinin: can its benefits be offset by harmful effects?. Transfusion, 1997, 37, 1105-1107.	1.6	5
146	Developing Peptide Inhibitors to Thrombin Activation of Platelets from Bradykinin Analogs. Thrombosis Research, 2001, 104, 451-465.	1.7	5
147	Factor XII gene mutation in the Hageman family. Journal of Thrombosis and Haemostasis, 2011, 9, 2329-2331.	3.8	5
148	Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. Haemophilia, 2020, 26, 601-606.	2.1	5
149	Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?. Journal of Clinical Investigation, 2011, 121, 4241-4243.	8.2	5
150	Electronically determined red cell indices in a predominantly black urban population of children 4 to 8 years of age. Journal of Pediatrics, 1974, 84, 559-561.	1.8	4
151	Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. Journal of Endotoxin Research, 2004, 10, 3-13.	2.5	4
152	A Platelet Acquired Storage Pool Disorder Associated with Tamoxifen Therapy. Case Reports in Hematology, 2012, 2012, 1-3.	0.4	4
153	Vascular Disease Patient Information Page: COVID-19-related thrombosis. Vascular Medicine, 2020, 25, 604-607.	1.5	4
154	Poly (acrylic acid) (PAA) is a contact system activator with properties to stop hemorrhage. Thrombosis Research, 2020, 193, 142-145.	1.7	4
155	Coagulation and Fibrinolysis. , 2011, , 785-800.		4
156	Ponatinib and Cardiovascular Complications. Blood, 2016, 128, 3055-3055.	1.4	4
157	Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 1084-1084.	1.4	4
158	Elevated neutrophil to lymphocyte ratio is associated with decreased amputation-free survival after femoropopliteal percutaneous revascularization. International Angiology, 2021, 40, 442-449.	0.9	4
159	Bradykinin – An elusive peptide in measuring and understanding. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12673.	2.3	4
160	Amyloid Î2-protein precursor: A new anticoagulant?. Translational Research, 1997, 130, 5-7.	2.3	3
161	Thrombosis in flowing blood. Blood, 2009, 114, 754-756.	1.4	3
162	Serpin targets in hemostasis/kinin formation. Blood, 2019, 134, 1566-1568.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab. <i>Frontiers in Medicine</i> , 2020, 7, 588526.	2.6	3
164	A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia. <i>Blood</i> , 2018, 132, 2475-2475.	1.4	3
165	Vascular Endothelial Cells Produce Coagulation Factors That Control Their Growth via Joint Protease-Activated Receptor and C5a Receptor 1 (CD88) Signaling. <i>American Journal of Pathology</i> , 2022, 192, 361-378.	3.8	3
166	Oscar D. Ratnoff: A man for all seasons. <i>Thrombosis and Haemostasis</i> , 2010, 104, 863-866.	3.4	2
167	Why do we want to know how factor XII levels are modulated?. <i>Thrombosis Research</i> , 2010, 125, 105-106.	1.7	2
168	Transmission of lupus anticoagulant by allogeneic stem cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 287-289.	0.7	2
169	Bilateral, Multiple, Episodic Retinal Vein Occlusions Associated With Common Variable Immunodeficiency. <i>JAMA Ophthalmology</i> , 2015, 133, 1216.	2.5	2
170	Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy. <i>Blood</i> , 2019, 134, 4934-4934.	1.4	2
171	Prolylcarboxypeptidase Promotes Endothelial Cell Proliferation and Vascular Repair. <i>Blood</i> , 2011, 118, 1142-1142.	1.4	2
172	Prolylcarboxypeptidase Murine Hypomorphs Are Hypertensive and Prothrombotic. <i>Blood</i> , 2008, 112, 3915-3915.	1.4	2
173	Neutrophil KLF2 Regulates Arterial and Venous Thrombosis. <i>Blood</i> , 2018, 132, 75-75.	1.4	2
174	Mice Deficient in Å2-Glycoprotein I Have a Delayed Time to Thrombosis. <i>Blood</i> , 2019, 134, 2423-2423.	1.4	2
175	Prekallikrein and Plasma Kallikrein. , 2013, , 2885-2892.		1
176	Coagulation Factor XIIa. , 2013, , 2881-2885.		1
177	Medically-Induced Hemophilia C to Treat Thrombosis. <i>Thrombosis Research</i> , 2015, 136, 185-186.	1.7	1
178	PolyPâ€™s many faces. <i>Blood</i> , 2016, 128, 1669-1670.	1.4	1
179	The amyloid beta-precursor proteinâ€™The unappreciated cerebral anticoagulant. <i>Thrombosis Research</i> , 2017, 155, 149-151.	1.7	1
180	Contact ignition by single-chain XIIa. <i>Blood</i> , 2017, 129, 1411-1412.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Persistent disseminated intravascular coagulation despite correction of endoleaks after thoracoabdominal endovascular aneurysm repair. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2021, 7, 730-733.	0.6	1
182	The Urokinase Plasminogen Activator Receptor Mediates ScuPA- or FXII-Induced Cell Growth and Proliferation through ERK1/2, Akt, and Beta-1-Integrin.. <i>Blood</i> , 2006, 108, 1817-1817.	1.4	1
183	A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation. <i>Blood</i> , 2016, 128, 3754-3754.	1.4	1
184	Angiotensin Receptor 2 Over-Expression: A Novel Physiologic Mechanism for Thrombosis Protection.. <i>Blood</i> , 2004, 104, 801-801.	1.4	1
185	Bradykinin B2 Receptor KO Mice Are Protected From Thrombosis by A Platelet Spreading Defect. <i>Blood</i> , 2010, 116, 3198-3198.	1.4	1
186	Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes. <i>Blood</i> , 2018, 132, 3800-3800.	1.4	1
187	Coagulation Factors. , 2007, , 1-6.		0
188	Coagulation Factor XIIa. , 2007, , 1-14.		0
189	Acute Leukemia. , 2011, , 235-250.		0
190	Thrombosis Prevention without Anticoagulation. <i>Frontiers in Medicine</i> , 2014, 1, 12.	2.6	0
191	Introduction to current issue. <i>Current Opinion in Hematology</i> , 2017, 24, 409-410.	2.5	0
192	Editorial: Introduction to the Presentations at the Factor XI and the Contact System SSC Session of the ISTH, Montpellier, France, May 27, 2016. <i>Frontiers in Medicine</i> , 2017, 4, 140.	2.6	0
193	130: OFF-PUMP CORONARY ARTERY BYPASS IN A PATIENT WITH INHERITED FACTOR V DEFICIENCY. <i>Critical Care Medicine</i> , 2018, 46, 48-48.	0.9	0
194	Editorial: Proceedings of KININ2018CLE, Cleveland, Ohio, June 18-20, 2018: A Compendium of the Presentations. <i>Frontiers in Medicine</i> , 2019, 6, 272.	2.6	0
195	Effect of the Neutrophil/Lymphocyte Ratio on Outcome after Carotid Endarterectomy and Carotid Artery Disease Progression. <i>Journal of the American College of Surgeons</i> , 2020, 231, S343.	0.5	0
196	Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy. <i>Frontiers in Medicine</i> , 2020, 7, 591546.	2.6	0
197	Factor XII's autoactivation and cell biology interdigitate in disease states. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1808-1812.	3.8	0
198	Mapping the Interaction of Peptide RPPGF with the Exodomain on Human Protease Activated Receptor 4 (PAR4).. <i>Blood</i> , 2004, 104, 1847-1847.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Over-Expression of Prolylcarboxypeptidase Enhances Plasma Prekallikrein Activation on Chinese Hamster Ovary Cell Membranes.. Blood, 2005, 106, 3698-3698.	1.4	0
200	Outside-In Signaling upon Assembly on Endothelial Cells of the Proteins of the Plasma Kallikrein/Kinin System.. Blood, 2005, 106, 1024-1024.	1.4	0
201	The Contributions of the P4-P2 Positions in PAR1 and 4 for Thrombin Recognition and Cleavage.. Blood, 2005, 106, 3574-3574.	1.4	0
202	Kallikrein. , 2007, , 1-15.		0
203	Deletion of Murine Kininogen Gene 1 (mKNG1) Causes Loss of Plasma Kininogen and Delays Thrombosis.. Blood, 2007, 110, 3625-3625.	1.4	0
204	Unique Thrombotic and Hemostatic Complications Associated with Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, , 695-715.		0
205	Prolylcarboxypeptidase Deficiency Is a Risk Factor for Arterial Thrombosis and Hypertension. Blood, 2010, 116, 651-651.	1.4	0
206	Over-Expression of the Mas Receptor Decreases Arterial Thrombosis Risk in B2R KO Mice by Elevating NO and Prostacyclin and Reducing GPVI Activation. Blood, 2011, 118, 700-700.	1.4	0
207	Leukocyte Factor XII Mediates Inflammation and Its Deficiency Promotes Wound Healing. Blood, 2012, 120, 616-616.	1.4	0
208	Discovery of new renal Ang II processing enzyme activity using mass spectrometry and gene deletion mouse models. FASEB Journal, 2013, 27, 1165.18.	0.5	0
209	Thrombosis Protection In Klkb1-/- (Prekallikrein KO) Mice Is Mediated By Increased Renal Mas Receptor, Plasma Prostacyclin, and Aortic Sirt1. Blood, 2013, 122, 195-195.	1.4	0
210	Prolylcarboxypeptidase Is a Risk Factor for Cardiovascular Events. Blood, 2014, 124, 1531-1531.	1.4	0
211	Leukocyte XII Regulates Venous Thrombosis Risk. Blood, 2015, 126, 238-238.	1.4	0
212	Abstract 037: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	0
213	Abstract 091: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	0
214	Physiology of Hemostasis. , 2019, , 81-88.		0
215	Correction to: Concise Guide to Hematology. , 2019, , C1-C1.		0